Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
about
Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agentInduction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantroneFormation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective EffectsHigh-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomesEffects of mitoxantrone on action potential and membrane currents in isolated cardiac myocytes.Inhibiting AKT phosphorylation employing non-cytotoxic anthraquinones ameliorates TH2 mediated allergic airways disease and rhinovirus exacerbation.Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.Synergistic and complete reversal of the multidrug resistance of mitoxantrone hydrochloride by three-in-one multifunctional lipid-sodium glycocholate nanocarriers based on simultaneous BCRP and Bcl-2 inhibition.CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity.Topoisomerase as target for antibacterial and anticancer drug discovery.Overcoming docetaxel resistance in prostate cancer: a perspective review.DNA topoisomerase-directed anticancerous alkaloids: ADMET-based screening, molecular docking, and dynamics simulation.Mitoxantrone, More than Just Another Topoisomerase II Poison.Anthraquinones As Pharmacological Tools and Drugs.Oestrone-targeted liposomes for mitoxantrone delivery via oestrogen receptor - synthesis, physicochemical characterization and in-vitro evaluation.Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.Total synthesis, cytotoxic effects of damnacanthal, nordamnacanthal and related anthraquinone analogues.Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.DNA topoisomerase-targeting chemotherapeutics: what's new?A novel DNA intercalator, 8-methoxy pyrimido[4',5':4,5]thieno (2,3-b)quinoline-4(3H)-one induces apoptosis in cancer cells, inhibits the tumor progression and enhances lifespan in mice with tumor.Mitoxantrone loaded superparamagnetic nanoparticles for drug targeting: a versatile and sensitive method for quantification of drug enrichment in rabbit tissues using HPLC-UVReversible and formaldehyde-mediated covalent binding of a bis-amino mitoxantrone analogue to DNA.Introductory remarks: immunosuppressive and immunomodulating drugs, where and how do they act?Mitoxantrone immunotherapy in multiple sclerosis.Localization and molecular interactions of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis.AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivoStudies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins.Tangential Flow Ultrafiltration Allows Purification and Concentration of Lauric Acid-/Albumin-Coated Particles for Improved Magnetic Treatment.Quantitative confocal spectral imaging analysis of mitoxantrone within living K562 cells: intracellular accumulation and distribution of monomers, aggregates, naphtoquinoxaline metabolite, and drug-target complexes.Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility.Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma.High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial.Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro.A theoretical study on interactions between mitoxantrone as an anticancer drug and DNA: application in drug design.Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice.Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.Isolation and structural analysis of the covalent adduct formed between a bis-amino mitoxantrone analogue and DNA: a pathway to major-minor groove cross-linked adducts.Safety, feasibility, and optimization of intra-arterial mitoxantrone delivery to gliomas.
P2860
Q24671854-FF2E6737-0251-407F-957D-E79692B3B258Q28377894-90D8A4C1-68CE-46B0-93DC-D617CD434C2CQ28468284-77A2A855-0707-43D3-B409-E2C9DB88D468Q33340182-356E890F-EE09-4C73-99CC-558325EC74C4Q34170191-70BB5903-317C-4B2B-83F5-F63FCA1F2B4BQ35028826-5A02429E-433B-410C-A0DD-FFA06924DD57Q35041389-F91A8EF3-D9C7-4261-AD27-89A9CA891CD5Q36420081-D3AA5F06-38F6-4090-8EE1-E9D41DB21564Q37214483-9FCF8647-8BC4-48C7-87D2-285841CE2EC5Q37406076-3434F605-ACA7-4B4D-A9D4-E45C5AC663C7Q37989563-EDCB7BBF-F517-41A9-BBDE-40CFCF04227EQ38057235-CE6DF896-DAE5-4FA0-9D8C-823310AB3DBDQ38392591-BB2233E3-3AFE-4774-887C-1AE3B52B37E8Q38569206-EEEA735E-F47A-47B7-851F-59F9FFB9576BQ38816745-97F0CBD9-17D2-4478-8F19-C8C73972BD2EQ38818984-C3E78CAF-E0D7-4EB5-86DE-115BE5C3FAF8Q38876257-C1E7EF19-9FFD-43B3-A8D4-E0BB6383A1B3Q39107017-025F05F0-9EB4-4D75-9BC9-7FE2EB6579ACQ39150971-4D989720-81DB-4643-B4AF-CDE6FA248E68Q39320242-68E58A54-6210-429C-9C20-29DFBC0F6C1CQ39418475-AD74CDA1-47C2-47BA-941C-9413C0FD1427Q40594307-FDA019C5-810D-40E5-BE2A-B083B3EA517CQ40689188-AFBF3D6C-649F-4855-BC9C-C7A3D734AED1Q41622065-A2F70D01-F549-4E2F-AB78-89DC2C6D9FCAQ41622099-71D5D2FB-6A48-49FE-AE72-303885BFBFEAQ41813215-09757718-873D-41E0-BA99-7069F21093A7Q41844441-1B55A774-D5A8-426F-ACEC-3A8DE648323AQ41845358-AAEE36C6-261A-4506-91EB-9C72D3050409Q41957148-CAB1C824-84C6-4F9B-AAD8-3B92ACFB5912Q42014456-F208ADCC-565E-4D8B-9245-24EFD62D46B4Q42069004-067599EE-9FAD-47FE-AE20-E6754E9B7052Q43412243-717E0167-54AA-4C80-9D0D-39F2353D1C84Q43561513-E3B4B143-EACD-424B-BFFD-9229979B5848Q44133294-7893C53E-6DBE-47D7-8739-F10DF6B7DE40Q46667848-696A35C3-18AA-46FD-953E-54C52AD88278Q47694093-60AEC4E0-506A-4BB7-8C97-72EC04EAFD34Q47839279-617F1122-8126-47E1-8897-DD133757A29FQ48053453-3EB7BD34-CD54-42AA-B288-A3615781BEEAQ48541574-8D5CA342-87DB-4778-B545-D0EEDB0F895F
P2860
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Mitoxantrone. A review of its ...... in the chemotherapy of cancer.
@ast
Mitoxantrone. A review of its ...... in the chemotherapy of cancer.
@en
type
label
Mitoxantrone. A review of its ...... in the chemotherapy of cancer.
@ast
Mitoxantrone. A review of its ...... in the chemotherapy of cancer.
@en
prefLabel
Mitoxantrone. A review of its ...... in the chemotherapy of cancer.
@ast
Mitoxantrone. A review of its ...... in the chemotherapy of cancer.
@en
P2093
P1433
P1476
Mitoxantrone. A review of its ...... in the chemotherapy of cancer.
@en
P2093
P304
P356
10.2165/00003495-199141030-00007
P577
1991-03-01T00:00:00Z
P6179
1024255294